GE Healthcare GEHC announced the launch of a new radiation therapy computed tomography (CT) solution, Revolution RT, which will likely create a more streamlined standard of care for cancer patients. The company unveiled the product at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2024 Congress. Apart from Revolution RT, the company also announced an updated and artificial intelligence (AI)-enhanced version of the Intelligent Radiation Therapy (iRT) platform at the ESTRO Congress. The company will also present the newly acquired MIM Software portfolio that will help it to build advanced AI and Digital solutions for more personalized oncology radiation therapy. GEHC has been actively building its AI-driven solutions portfolio with the addition of several new services or products so far in 2024. The medical sector or the medical device companies in particular, have shown rapid adoption of AI to build more precise and accurate devices catering to various categories of the healthcare industry. This innovation in AI should help GEHC to boost its market presence in the medical devices market going forward. Revolution RT GE Healthcare's Revolution RT is set to enhance CT imaging accuracy in radiation therapy. It features a wide-bore CT platform that offers precision simulation and reduced workflow complexity, with the goal of expedited patient care. The company developed the Revolution RT with advanced capabilities for radiation therapy simulation, diagnostics and interventions. This design aims to cater to a larger number of patients and establish a more efficient standard of care. The Revolution RT incorporates precision radiotherapy simulation to enhance imaging accuracy, and improve workflow and efficiency. It also utilizes deep learning technology for accurate patient imaging. iRT Platform Upgrade The updated platform enables greater interoperability, connectivity and efficiency throughout the entirety of the radiation oncology care continuum. It also includes an integrated workflow that connects various applications to an intuitive single interface. Apart from these, it also offers multi-vendor interoperability, seamless data transfer and task automation, and a catalog of RT applications. This AI-enhanced platform now interfaces with the Spectronic magnetic resonance imaging (MRI) Planner. It will use AI to convert MR simulation images into an equivalent CT image that can be used for RT dose calculation. The iRT platform will also offer a novel approach to treatment plan creation while the patient is still on the simulation table. This can potentially reduce the time between simulation and the first radiation dose. The new version of iRT is also updated to allow user-enabled personalization, analytics and notification modules. GE HealthCare Technologies Inc. Price GE HealthCare Technologies Inc. Price GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote Notable Developments GE Healthcare and the Radiological Society of North America announced their partnership to offer mammography equipment, training and educational materials to the radiologists at Muhimbili National Hospital, part of the Muhimbili University of Health and Sciences, Tanzania, last month. The deal is likely to increase screening availability and assist medical professionals in reducing the nation's breast cancer death rate. In April, GEHC announced its latest breast cancer detection technology during the Society of Breast Imaging Symposium in Montreal, Canada. The showcase featured the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite and Pristina Bright to demonstrate the company’s personalized approach to transforming breast cancer imaging. The company announced the launch of the Prostate Volume Assist (PVA) urology-based AI software feature in March. Zacks Rank and Stocks to Consider GE Healthcare currently carries a Zacks Rank #3 (Hold) Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Ecolab ECL and Boston Scientific Corporation BSX. Align Technology, carrying a Zacks Rank of 2 (Buy) at present, reported first-quarter 2024 adjusted earnings per share (EPS) of $2.14, which beat the Zacks Consensus Estimate by 8.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $997.4 million outpaced the consensus mark by 2.6%. Align Technology has a long-term estimated growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.7%. Ecolab’s shares have risen 33.8% against the industry’s 9.3% decline in the past year. Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. The company currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX):Free Stock Analysis Report Ecolab Inc. (ECL):Free Stock Analysis Report Align Technology, Inc. (ALGN):Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...